Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of CTP-543 in Hepatic Impairment
NCT05467722Phase 1Completed
- Sponsor
- Concert Pharmaceuticals
- Start
- Jun 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of deuruxolitinib in alopecia areata (2 arms), sponsored by Concert Pharmaceuticals. Primary endpoints: Maximum observed concentration, Area Under the Concentration-Time Curve from time zero to last non-zero concentration and 1 more. Started Jun 2022; status: completed.
02
Drugs
deuruxolitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT05467722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05467722.